The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...
In recent years, the complement system has been implicated in the pathophysiology and progression of many disorders, notably modulating inflammation and causing endothelial and organ damage 1. Acute ...